Lecanemab in Early Alzheimer’s Disease

Christopher H. van Dyck et al.

Primary endpoint

Core Study: Change from Baseline in the CDR-SB at 18 Months

Population

Early Alzheimer's Disease; n=1906

doi:10.1056/NEJMoa2212948

Historical

Current

Future

3 noemes

Historical

1 noeme

Published findings from this trial. Vote whether the expert body still believes each noeme stands given current evidence.

The CLARITY-AD (lecanemab) trial's stated primary conclusion — Lecanemab slows cognitive decline in early Alzheimer disease with amyloid confirmation, with a non-trivial ARIA safety signal. — replicates in independent cohorts.

neurology

Current

1 noeme

Noemes tracking active replication, subgroup analysis, or long-term follow-up. Vote on the likelihood the original effect holds.

Recent follow-up analyses of CLARITY-AD (lecanemab) are confirming the original effect size in real-world data.

neurology

Future

1 noeme

Open forecast horizons tied to this trial. Vote your probability that each resolves TRUE by the declared horizon.

By 2028, anti-amyloid antibodies will have a net positive impact on real-world CDR-SB trajectories, but uptake will remain <25% of eligible early AD patients due to ARIA monitoring burden.

neurology

71%

Semantically related trials

Nearest trials by noeme-centroid cosine distance. Lower = closer.

NCT02484547

0.1121

· 3 claims

A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease

NCT00829166

0.2266

· 3 claims

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

NCT01035255

0.2460

· 3 claims

Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure

NCT02386553

0.2465

· 3 claims

An Open-Label Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ISIS 396443 Delivered Intrathecally to Subjects With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy

NCT00354133

0.2481

· 3 claims

Neurostimulation for Parkinson's Disease with Early Motor Complications

NCT03777059

0.2506

· 3 claims

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine (ADVANCE)